Completed PHASE1 INTERVENTIONAL NCT01613573

Crossover Study to Assess the Safety and Pharmacokinetic of Pegylated Somatropin(PEG Somatropin) in GHD Children (Phase 1)

A Phase 1, Open-Label, Single and Multiple Dose Study to Assess the Safety and Pharmacokinetics of Pegylated Somatropin(PEG Somatropin) in GHD Children

Sponsor: Changchun GeneScience Pharmaceutical Co., Ltd.

Conditions Growth Hormone Deficiency

Interventions pegylated somatropin somatropin AQ

Updated 6 times since 2017 Last updated: Jun 13, 2012 Started: Mar 31, 2010 Primary completion: Oct 31, 2010 Completion: Nov 30, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01613573, this PHASE1 trial focuses on Growth Hormone Deficiency and remains completed. Sponsored by Changchun GeneScience Pharmaceutical Co., Ltd., it has been updated 6 times since 2010, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Oct 2023 — Jul 2024 [monthly]

Completed PHASE1
Jan 2021 — Oct 2023 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE1

First recorded

Mar 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Changchun GeneScience Pharmaceutical Co., Ltd.
Huazhong University of Science and Technology

Data source: Changchun GeneScience Pharmaceutical Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.